Work

Poster: CLL-118 A Phase 1 Study With the Novel B-Cell Lymphoma 2 Inhibitor BGB-11417 as Monotherapy or in Combination With Zanubrutinib in Patients With B-Cell Malignancies: Preliminary Data

Year: 2022

Type: article

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(22)00844-8

Authors: Jacob D. Soumerai, Stephen Opat, Chan Y. Cheah, Masa Lasica, Emma Verner, Peter J. Browett, Henry Chan, Eva González Barca, James Hilger, Yiqian Fang, David Simpson, Constantine S. Tam

Institutions: Harvard University, Massachusetts General Hospital, Monash Health, Monash University, The University of Western Australia, Sir Charles Gairdner Hospital, Linear Clinical Research, Pathwest Laboratory Medicine, St Vincent's Hospital Melbourne, The University of Sydney, Concord Repatriation General Hospital, Auckland City Hospital, North Shore Hospital, Institut d'Investigació Biomédica de Bellvitge, Institut Català d'Oncologia, Universitat de Barcelona, The Royal Melbourne Hospital, The University of Melbourne, Peter MacCallum Cancer Centre

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4296532835

FWCI:

Cites:

Cited by:

Related to: 10